Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Chief Financial Officer | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 64,449 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Sale · Disposed 893 · Balance 64,528 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-10-05 · Sale · Disposed 79 · Balance 64,449 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 79 | $3.57 | $282.03 |
DisclosureSEC source: 0001983944-26-000014 · form4-10062026_081052.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,449 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 893 | $3.47 | $3,098.71 |
DisclosureSEC source: 0001983944-26-000014 · form4-10062026_081052.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,528 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001983944-26-000010 · form4-07172026_040708.xml · derivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2036-07-15 F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 15, 2027 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 104 | $4.31 | $448.24 |
DisclosureSEC source: 0001983944-26-000008 · form4-07072026_050702.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,441 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 819 | $4.27 | $3,497.13 |
DisclosureSEC source: 0001983944-26-000008 · form4-07072026_050702.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,545 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| April 06, 2026 Filed Apr 6, 2026 22:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 102 | $5.05 | $515.10 |
DisclosureSEC source: 0001983944-26-000006 · form4-04062026_060407.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,364 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 22:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 799 | $4.91 | $3,923.09 |
DisclosureSEC source: 0001983944-26-000006 · form4-04062026_060407.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,466 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $4.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:01 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 58,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001983944-26-000004 · form4-02052026_120235.xml · derivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,000 Underlying: Ordinary Shares · 58,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on February 3, 2027 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,115 | $6.45 | $7,191.75 |
DisclosureSEC source: 0001983944-26-000002 · form4-01062026_080126.xml · nonDerivative · entry 3 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,265 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001983944-26-000002 · form4-01062026_080126.xml · derivative · entry 4 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires 2036-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,317 | $6.80 | $8,955.60 |
DisclosureSEC source: 0001983944-26-000002 · form4-01062026_080126.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,380 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001983944-26-000002 · form4-01062026_080126.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,697 F1 · shares: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 103 | $8.41 | $866.23 |
DisclosureSEC source: 0001983944-25-000003 · form4-10062025_041003.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,197 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.40 to $8.50 inclusive. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 221 | $8.40 | $1,856.40 |
DisclosureSEC source: 0001983944-25-000003 · form4-10062025_041003.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,300 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.37 to $8.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 21:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 100 | $7.44 | $744.00 |
DisclosureSEC source: 0001415889-25-019424 · form4-07072025_050703.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,521 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.405 to $7.483 inclusive. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 21:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 206 | $7.09 | $1,460.54 |
DisclosureSEC source: 0001415889-25-019424 · form4-07072025_050703.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,621 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.09 to $7.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 21:35 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 109 | $7.48 | $815.32 |
DisclosureSEC source: 0001415889-25-010240 · form4-04042025_050401.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,827 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.45 to $7.50 inclusive. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 21:35 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 210 | $8.02 | $1,684.20 |
DisclosureSEC source: 0001415889-25-010240 · form4-04042025_050401.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,936 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,686 | $15.00 | $40,290.00 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 4 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,146 F6 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 159 | $14.75 | $2,345.25 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 3 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,832 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.69 to $14.75 inclusive. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 43,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · derivative · entry 5 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires 2035-01-02 F7 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,750 | $14.09 | $24,657.50 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,991 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,741 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,109 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 12 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,954 Underlying: Ordinary Shares · 1,109 shares Expires 2029-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 154 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 11 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302 Underlying: Ordinary Shares · 154 shares Expires 2029-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,312 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 10 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,617 Underlying: Ordinary Shares · 1,312 shares Expires 2028-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 231 | $24.82 | $5,733.42 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 9 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,241 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $24.825 inclusive. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 209 | $24.77 | $5,176.93 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 8 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,472 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.73 to $24.81 inclusive. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,241 | $25.21 | $81,705.61 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 7 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,681 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,109 | $25.05 | $27,780.45 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 6 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,922 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6). Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 1,109 | $9.82 | $10,890.38 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 5 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 154 | $25.01 | $3,851.54 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 4 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,922 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.08 inclusive. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 154 | $8.21 | $1,264.34 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 3 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,312 | $25.05 | $32,865.60 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,922 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6). Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 1,312 | $1.87 | $2,453.44 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:50 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 153 | $22.26 | $3,405.78 |
DisclosureSEC source: 0001415889-24-024767 · form4-10042024_041001.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,922 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 22:55 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 148 | $19.64 | $2,906.72 |
DisclosureSEC source: 0001415889-24-019387 · form4-07082024_060709.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,075 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 152 | $23.81 | $3,619.12 |
DisclosureSEC source: 0001415889-24-010413 · form4-04052024_040425.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,223 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 23:36 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 604 | $17.50 | $10,570.00 |
DisclosureSEC source: 0001209191-24-000890 · doc4.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,375 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:36 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0001209191-24-000890 · doc4.xml · derivative · entry 3 Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Ordinary Shares · 31,000 shares Expires 2034-01-02 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:36 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000890 · doc4.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,979 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 21:50 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 54 | $20.00 | $1,080.00 |
DisclosureSEC source: 0001209191-23-052254 · doc4.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,979 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:57 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 61 | $25.10 | $1,531.10 |
DisclosureSEC source: 0001209191-23-041578 · doc4.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,033 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.